Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Peptides for Coronavirus Research

Coronaviruses Peptide Tools to Study Coronaviruses The coronavirus family comprises several viruses such as Severe acute respiratory syndrome coronavirus (SARS-CoV) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Middle East respiratory syndrome-r

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Coronaviruses

Peptide Tools to Study Coronaviruses

The coronavirus family comprises several viruses such as

Severe acute respiratory syndrome coronavirus (SARS-CoV)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Middle East respiratory syndrome-related coronavirus (MERS)

Common cold coronaviruses HCoV 229E, OC43, HKU1 and NL63

Various animal coronaviruses

Coronaviruses have a positive-sense single-stranded RNA genome and characteristic spikes on their surface, which create an image reminding of the solar corona. The spikes are composed of Spike proteins (S protein) which contain two subunits. Subunit S1 forms the spike head with the receptor binding domain (RBD). Subunit S2 forms the stem and enables fusion with the host cell. S1 proteins are the most variable components of the virus as they are responsible for host cell specificity. Spike protein, membrane protein (M) and envelope protein (E) are anchored in the viral envelope, a lipid bilayer.

JPT is an expert for manufacturing a wide variety of synthetic peptide formats for research and clinical applications in the development of immunotherapy and vaccines and immune monitoring. Our researchers constantly develop new products for well-known infectious diseases such as HIV, TB or HBV as well as newly emerging diseases such as MERS, SARS and COVID-19.

JPT's Coronavirus Peptide Tools

Filter products

T-cell immunity

Epitope Mapping Peptide Sets

PepMix Peptide Pools

PepMix Peptide Pools Infections

Common cold

Covid-19

Infection

Middle Eastern Respiratory Syndrome (MERS)

Respiratory infection

Severe acute respiratory syndrome (SARS)

Human coronavirus (HCoV)

MERS-CoV (Middle East respiratory syndrome-related coronavirus)

SARS-CoV (Severe acute respiratory syndrome coronavirus)

Nucleoprotein

Spike glycoprotein

No

Epitope Mapping Peptide Set (EMPS) HCoV-229E (Spike Glycoprotein)

US$6,243.90

Epitope Mapping Peptide Set (EMPS) HCoV-HKU1 (Spike Glycoprotein)

Epitope Mapping Peptide Set (EMPS) HCoV-NL63 (Spike Glycoprotein)

Epitope Mapping Peptide Set (EMPS) HCoV-OC43 (Spike Glycoprotein)

Epitope Mapping Peptide Set (EMPS) MERS-CoV (Spike Glycoprotein)

PepMix™ HCoV-229E (NCAP)

US$551.20

PepMix™ HCoV-229E (Spike Glycoprotein)

US$1,158.30

PepMix™ HCoV-HKU1 (NCAP)

US$574.60

PepMix™ HCoV-HKU1 (Spike Glycoprotein)

US$1,621.10

PepMix™ HCoV-NL63 (NCAP)

Cellular Immunity

Antigen-specific T-cell stimulation

Cellular immune monitoring

Vaccine target discovery

Blood test development

Cross reactivity testing between viruses

Cell therapy development

Efficient epitope mapping and identification

Matrix Pools and individual peptides spanning a whole antigen in one set

Minimal sample amount required

Humoral Immunity

Humoral immune monitoring

Antibody epitope discovery

Serological test development discovery

Cross-reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)

Screening individual antigens of SARS-CoV-2 and SARS

PepStar™ Pan Coronavirus

Thousands of peptides spanning entire antigens or genomes

Incubation using smallest sample volumes

Study of antibody cross-reactivities between SARS-CoV-2 and other corona viruses

Verification of peptide binders with a large numbers of samples

Transfer of results to ELISA platform for rapid test development

Peptide ELISA development and service using virus antigen peptides

ELISA-based validation service of peptide binders identified by using JPT’s peptide microarray platform

Collaborative ELISA test development

Clinical Trial Immune Monitoring & Cell Therapy

High quality chemically synthesized antigen source for vaccine trial monitoring

Ancillary reagents for cellular therapy development

Full analytical coverage, stability testing, batch documentation and more

Proteomics

Peptide pool of stable isotope labeled peptides from relevant SARS CoV-2 antigens

Identify and quantify virus antigens from biological samples using mass spectrometry based assays (MRM)

Screen 23 ready-made proteotypic peptides from SARS-CoV-2

Or order your custom SpikeMix™

References

Influenza vaccination post-COVID-19 expands vaccine-specific effector CD4 T-cells and Tregs under positive influence of host trained innate immunityBindhu et al., NPJ Vaccines (2025) - PMID: 41453905Products used: PepMix™ HCoV-HKU1 (Spike Glycoprotein), PepMix™ Influenza B (HA/H0N0/Phuket/2013), PepMix™ Influenza A (NP/AnnArbor (H2N2), PepMix™ Influenza B (HA/H0N0/Austria/2021), PepMix™ Influenza A (HA/H3N2/Darwin/2021), PepMix™ Influenza A (HA/H1N1/Victoria/2019)

Lung transplantation in times of Covid-19 – Immune response and clinical management of recent lung allograft recipients infected with SARS-CoV 2Glück et al., Dissertation (2025)

Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal modelsMaghibosadat et al., Journal of Virology (2025) - PMID: 39817773Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HCoV-229E (Spike Glycoprotein)

Comparative analysis of adaptive immunity to SARS-CoV-2 in infected children and adults Nantel et al., Pediatric Research (2025) - PMID: 40836106 Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta), PepMix™ SARS-CoV-2 (Spike P.1 / Gamma), PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ HCoV-OC43 (Spike Glycoprotein), PepMix™ HCoV-HKU1 (Spike Glycoprotein)

Cellular and humoral immunity towards SARS-CoV-2 infection and vaccination in patients with primary antibody deficiencySteiner, Dissertation (2025) Product used: PepMix™ SARS-CoV-2 (NCAP), PepMix™ HCoV-OC43 (Spike Glycoprotein), PepMix™ HCoV-229E (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infectionWeigl et al., PLOS One (2025) - PMID: 40498720Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (NCAP), PepMix™ HCoV-229E (Spike Glycoprotein), PepMix™ HCoV-OC43 (Spike Glycoprotein), PepMix™ HCoV-NL63 (Spike Glycoprotein), PepMix™ HCoV-HKU1 (Spike Glycoprotein)

Emerging mutation in SARS-CoV-2 facilitates escape from NK cell recognition and associates with enhanced viral fitnessBilev et al., PLOS Pathogens (2024) - PMID: 39652590Products used: Custom Peptide Synthesis, Single Antigen peptides covering, HCov, Sars-CoV-2

Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIVNguni et al., Frontiers in Immunology (2024) - PMID: 38343437Products used: PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ HCoV-NL63 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)

Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinaseMyeni et al., Nature Communications (2023)Product used: PepMix MERS-CoV (Spike Glycoprotein)

Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV Ng'uni et al., Frontiers in Immunology (2024) Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), HCoV-NL63 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.351 / Beta)

Immune profling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients Tornesello et al., Journal of Translational Medicine (2023) Product used: PepStar Antigen Collection Pan-Coronavirus

Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase Myeni et al., Nature Communications (2023) Product used: PepMix MERS-CoV (Spike Glycoprotein)

T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific componentsLichen Jing et al., MedRxiv et al., (2022)Products used: PepMix™ HCoV-OC43 (Spike Glycoprotein)

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman PrimatesCorbett et al, New England J of Med (2020)

Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy DonorsBraun et al, Nature (2020)

Single-shot Ad26 Vaccine Protects against SARS-CoV-2 in Rhesus MacaquesMercado et al, Nature (2020)

Safety and Immunogenicity of a Modified Vaccinia Virus Ankara Vector Vaccine Candidate for Middle East Respiratory Syndrome: an Open-Label, Phase 1 TrialKoch et al, Lancet (2020)

Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and TestingZecha et al, Mol Cell Proteomics (2020)

Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in MiceMcKay et al, Nature 2020

The Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for MERS-CoV Infection as Identified by Temporal Kinome AnalysisKindrachuk et al, Antimicrob Agents Chemother. (2014)

Application Note

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What If Reconstituted Peptide Appears Cloudy or Discoloured?

Discard immediately. Cloudiness indicates protein aggregation or bacterial contamination. Properly reconstituted peptides should be clear and colourless. Aggregated peptides lose bioactivity and can produce inconsistent results across experimental replicates. Use bacteriostatic water for reconstitution, refrigerate at 2–8°C, and use within 28 days. Temperature excursions above 8°C cause irreversible denaturation.

Source: realpeptides.co ↗
02What If BPC-157 Shows Muscle Gain Without Increased Protein Synthesis Markers?

This is expected. BPC-157's mechanism operates upstream of protein synthesis. The muscle gain observed in aged rodent models treated with BPC-157 is driven by improved capillary density and nutrient delivery, not increased mTOR activation. If your assays are measuring phosphorylated S6 kinase or 4E-BP1 (direct mTOR pathway markers), you won't detect BPC-157's effect. Instead, measure VEGF expression, capillary-to-fibre ratio, or tissue oxygen saturation. Those are the variables BPC-157 modulates. Expecting it to behave like a direct anabolic agent misinterprets the mechanism entirely.

Source: realpeptides.co ↗
03What If a Research Subject Experiences Vivid Dreams or REM Rebound on MK 677?

Reduce the dose to 10 mg nightly and administer earlier in the evening (6–8 hours before bed) rather than immediately before sleep. MK 677's enhancement of REM sleep density can produce intense, vivid dreaming in subjects unaccustomed to high REM pressure. This is not pathological but may disrupt subjective sleep quality. Some protocols incorporate a titration schedule starting at 5 mg and increasing by 5 mg weekly to allow gradual adaptation. If vivid dreaming persists despite dose reduction, consider switching to a selective SWS-enhancing protocol using Ipamorelin, which affects slow-wave sleep architecture without comparable REM intensification.

Source: realpeptides.co ↗
04What If I Use DSIP During My Night Shift to Stay Alert?

Do not use DSIP during wakefulness windows. It induces delta-wave sleep within 30–45 minutes of administration and will impair alertness for 4–6 hours. DSIP is exclusively a post-shift intervention for daytime sleep induction. If you need wakefulness support during night shifts, Semax at 300–600 mcg intranasal provides cognitive support without sedation, but it's not a stimulant and won't override severe sleep deprivation.

Source: realpeptides.co ↗
05What If Preliminary Data Suggests a Peptide Worsens Outcomes in a Subgroup?

Stop and characterize the subgroup before modifying the protocol. Natriuretic peptides can cause hypotension in patients with preserved ejection fraction and normal filling pressures. Giving BNP to diastolic heart failure patients without volume overload produces harm, not benefit. Similarly, immune-stimulating peptides like thymosin alpha-1 may worsen autoimmune-mediated myocarditis even as they improve sepsis-related cardiac depression. Heterogeneity in treatment response is itself a research finding. It identifies which pathophysiological mechanism drives disease in that subset.

Source: realpeptides.co ↗
comparison

Peptides for Mold Illness: Full Protocol Comparison

This table compares the three primary peptides used in clinical CIRS protocols, their mechanisms, dosing, and application timing. Thymosin Alpha-1 Modulates T-cell differentiation; reduces …

Source: realpeptides.co
comparison

Peptides for HSDD Research: Mechanism Comparison

Kisspeptin-54 (full-length) GPR54 (KISS1R) <30 minutes Poor (requires ICV) Modeling pulsatile GnRH secretion and HPG axis restoration Gold standard for upstream hormonal models but impracti…

Source: realpeptides.co
comparison

Peptides for Golf Recovery Protocol Evidence Guide: Comparison

| Peptide | Primary Mechanism | Optimal Dose | Administration Frequency | Tissue Target | Clinical Evidence Strength | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, a…

Source: realpeptides.co
Research context

Read sources and limitations before applying a claim.

Peptides for Cellular Senescence Research Compared: Efficacy, Limitations, and Selection Criteria

Epithalon (AEDG) Telomerase activation via TERT upregulation Replicative senescence in proliferation-competent cells 1–10 µg/mL every 48 hours for 10–14 days No effect on post-mitotic cells or cells already senescent Use only for prevention studies in actively dividing cultures. Not for clearance FOXO4-DRI FOXO4-p53 disruption inducing p53-mediated apoptosis Therapy-induced, oncogene-induced senescence with intact p53 5–20 µM for 24–72 hours Fails in p53-mutant or p53-null cells (40%+ of aged tissues) Most potent senolytic available. But requires p53 functional validation before use GHK-Cu NF-κB inhibition and SASP suppression via copper-dependent transcription factor modulation Inflammatory SASP mitigation without cell removal 1–10 µM continuously in culture medium Does not clear senescent cells. Only reduces secretory output Best for tissue contexts where senolytic clearance risks structural damage

Source: realpeptides.co ↗

The Mechanistic Truth About Peptides for Ulcerative Colitis Research Compared

Here's the honest answer: peptides for ulcerative colitis research don't fail because the mechanisms are wrong. They fail because research protocols ignore half-life pharmacokinetics, use suppliers without sequence verification, and assume oral bioavailability exists for peptides that pancreatic enzymes destroy completely. BPC-157 works, but not at the single daily dosing most protocols use. LL-37 restores barrier function, but only when it actually contacts colonic mucosa rather than getting degraded in the stomach. Thymosin beta-4 mobilizes stem cells effectively, but zero percent survives oral administration regardless of dose. The gap between published research showing 60–70% histological improvement and failed replication attempts comes down to these overlooked variables. Not the peptides themselves. We mean this sincerely: amino acid sequence verification costs $150 per peptide and prevents 80% of the 'this compound didn't work' scenarios we see across research labs. Our work with research teams in this space consistently shows that BPC-157 and KPV produce the most reliable results when protocol variables are controlled. BPC-157's stability across administration routes and KPV's intact intestinal absorption make them forgiving choices for initial colitis model work. LL-37 and thymosin beta-4 deliver powerful effects when administered correctly but require more precise protocol adherence. LL-37 demands mucosal delivery, and thymosin beta-4 demands parenteral dosing with no exceptions. The choice between peptides isn't about 'which is best' but which mechanism aligns with your research question: vascular repair (BPC-157), barrier restoration (LL-37), stem cell mobilization (thymosin beta-4), or localized anti-inflammatory signaling (KPV). Each addresses a different component of ulcerative colitis pathology. Research-grade peptides targeting inflammatory bowel disease mechanisms demand precision at every stage. From synthesis verification through storage protocols to administration timing. The difference between a peptide that demonstrates measurable histological improvement and one that produces no detectable effect often comes down to variables invisible in published methods sections: reconstitution technique, storage temperature excursions during shipping, or dosing frequency misaligned with peptide half-life. Our dedication to quality extends across Real Peptides' entire catalog, where exact amino acid sequencing and small-batch synthesis eliminate the sequence errors and stability failures that compromise research outcomes. Explore high-purity research peptides designed for protocols where precision determines whether your model shows the effects published literature predicts or none at all.

Source: realpeptides.co ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols and Bioavailability Variables

Semax is typically administered intranasally at 300–600 mcg per dose in research settings. Intranasal delivery achieves CNS concentrations 2–3 times higher than subcutaneous injection due to direct olfactory nerve transport bypassing first-pass hepatic metabolism. Plasma peak occurs 15–20 minutes post-administration with measurable BDNF elevation beginning at 30 minutes and persisting for 4–6 hours. Selank dosing ranges from 300 mcg to 3 mg depending on protocol design, with most cognitive research using 600–900 mcg intranasally. Its shorter half-life (approximately 30 minutes) means researchers often implement twice-daily dosing to maintain stable anxiolytic effects. Subcutaneous administration extends duration slightly (45–60 minutes) but reduces bioavailability by approximately 40% compared to intranasal routes. N-Acetyl Semax AVP demonstrates dose-dependent effects: 300–600 mcg produces mild cognitive enhancement, while 1.2–2.4 mg generates measurable dopaminergic activation detectable via PET imaging studies. The acetylation allows once-daily dosing where Semax would require three administrations to maintain similar plasma exposure over 24 hours. Reconstitution differences matter significantly. All three peptides arrive as lyophilised powder requiring reconstitution with bacteriostatic water (0.9% benzyl alcohol as preservative). Semax and Selank are stable at −20°C in powder form for 24+ months, but once reconstituted must be refrigerated at 2–8°C and used within 60 da…

Source: realpeptides.co ↗
Potential benefits

Immunomodulatory benefits of LL-37

The reported immune-assisting benefits of this peptide include: Control of fungal invasion A viable alternative to antibiotics Regulation of bacterial intrusion Antiviral effects Quick recuperation from wounds and injuries Stimulation of immune cells

Source: livvnatural.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

New in: JPT's Bone Healing Peptides!

NEW: Bone Healing Peptides for Research! Published on 14/07/2026 Understanding the molecular mechanisms behind bone regeneration is essential for advancing orthopedic research and regenerative medicine. By mim…

Read guide →
04
Peptide Therapy Guide Editorial Team

Peptides for Bioanalysis

Bioanalysis Peptides In Bioanalysis we measure drugs and their metabolites, as well as biological molecules such as macromolecules, proteins, DNA, large molecule drugs, and metabolites in biological systems. J…

Read guide →